Clinical trials in thrombolytic therapy, part 1: Outcome markers that go beyond mortality reduction

American Journal of Health-System Pharmacy

Volumn 54, Issue SUPPL. 1, 1997, Pages

  Stringer, Kathleen A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Clinical effectiveness; Clinical studies; Economics; Mortality; Myocardial infarction; Outcomes; Thrombolytic agents

Indexed keywords

ALTEPLASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY BLOOD FLOW; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG POTENCY; FIBRINOLYTIC THERAPY; HUMAN; MEDICAL DECISION MAKING; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030721729     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.suppl_1.s23     Document Type: Conference Paper

References (17)

1. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993; 329:673-82.
2. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993; 329:1615-22.
3. Simoons ML, Maggioni AP, Knatterud G et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet. 1993; 342:1523-8.
4. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327:685-91.
5. Pfeffer MA, Braunwald E, Moyé LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992; 327:669-77.
6. Lenderlink T, Simoons ML, Van Es G-A et al. , for the European Cooperative Study Group. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. Circulation. 1995; 92:1110-6.
7. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase doublebolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet. 1995; 346:329-36.
8. Schröder R, Wegscheider K, Schröder K et al. , for the INJECT Trial Group. Extent of early ST-segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. J Am Coll Cardiol. 1995; 26:1657-64.
9. Barbash GI, Roth A, Hod H et al. Rapid resolution of ST elevation and prediction of clinical outcome in patients undergoing thrombolysis with alteplase (recombinant tissue-type plasminogen activator): results of the Israeli Study of Early Intervention in Myocardial Infarction. Br Heart J. 1990; 64:241-7.
10. Saran RK, Been M, Furniss SS et al. Reduction in ST segment elevation after thrombolysis predicts either coronary reperfusion or preservation of left ventricular function. Br Heart J. 1990; 64:113-7.
11. Mauri F, Maggioni AP, Franzosi MG et al. , for the GISSI-2 Investigators. A simple electrocardiographic predictor of the outcome of patients with acute myocardial infarction treated with a thrombolytic agent. A Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2)-derived analysis. J Am Coll Cardiol. 1994; 24:600-7.
12. Dissmann R, Schröder R, Busse U et al. Early assessment of outcome by ST-segment analysis after thrombolytic therapy in acute myocardial infarction. Am Heart J. 1994; 128:851-7.
13. Schröder R, Dissmann R, Brüggemann T et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol. 1994; 24:384-91.
14. Shah PK, Cercek B, Lew AS. Angiographic validation of bedside markers of reperfusion. J Am Coll Cardiol 1993; 21:55-61.
15. Baigent C, Collins R. ISIS-2. 4-Year mortality follow-up of 17,187 patients after fibrinolytic and anti-platelet therapy in suspected acute myocardial infarction. Circulation. 1993; 88(suppl 1):I-291. Abstract.
16. Terrin ML, Williams DO, Kleiman NS et al. Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. J Am Coll Cardiol 1993; 22:1763-72.
17. Coyne KS, Walker PL, Reiner JS et al. Cardiac specific two-year mortality related to initial post-thrombolytic flow grade. J Am Coll Cardiol 1996; 27:12A. Abstract.